Valuation : Insulet Corporation

Market Cap 9.34B 8.03B 7.58B 6.9B 12.91B 893B 13.02B 90.27B 34.74B 453B 35.08B 34.31B 1,439B P/E 2026 *
21.9x
P/E 2027 * 17.7x
Enterprise Value 9.39B 8.08B 7.62B 6.94B 12.98B 898B 13.09B 90.75B 34.93B 455B 35.26B 34.49B 1,446B EV / Sales 2026 *
2.86x
EV / Sales 2027 * 2.41x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day-0.99%
1 week-10.56%
Current month-9.40%
1 month-5.72%
3 months-10.64%
6 months-43.47%
Current year-52.62%
1 week 134.11
Extreme 134.11
147.39
1 month 134.11
Extreme 134.11
155.17
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 27/04/2025
Director of Finance/CFO 53 29/09/2025
Compliance Officer 50 30/11/2022
Director TitleAgeSince
Director/Board Member 61 26/07/2015
Director/Board Member 59 09/08/2017
Director/Board Member 54 19/10/2020
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/26 Buy

Chief Executive Officer

1,100 0.0016%
01/08/26 Tax

Head of Human Resources

-244 0.0003%
01/07/26 Free

Director

1,355 0.0019%
Change 5-day change 1-year change 3-year change Capi.($)
-1.06%-10.56%-60.11%-21.66% 9.34B
-0.53%-4.99%-20.10%+2.61% 179B
+0.12%-1.59%-0.76%+14.58% 117B
-0.13%-4.82%+8.31%+80.61% 61.25B
-1.92%-6.01%+8.80%+41.11% 50.24B
+0.24%-5.97%-6.37%-33.87% 48.05B
+0.56%-5.80%+11.20%-19.01% 31.89B
-0.57%-11.48% - - 28.42B
+0.07%+0.44%+34.88%-12.44% 24.23B
+0.49%-7.65%-12.44%+4.86% 21.4B
Average -0.29%-5.35%-4.06%+6.31% 57.09B
Weighted average by Cap. -0.36%-4.29%-4.91%+12.07%

Financials

2026 *2027 *
Net sales 3.29B 2.83B 2.67B 2.43B 4.54B 314B 4.58B 31.77B 12.23B 159B 12.35B 12.08B 506B 3.74B 3.22B 3.04B 2.77B 5.17B 358B 5.22B 36.18B 13.93B 182B 14.06B 13.75B 577B
Net income 427M 367M 346M 315M 590M 40.79B 595M 4.12B 1.59B 20.69B 1.6B 1.57B 65.71B 535M 460M 434M 396M 740M 51.18B 746M 5.17B 1.99B 25.96B 2.01B 1.97B 82.45B
Net Debt 49.62M 42.68M 40.27M 36.68M 68.57M 4.74B 69.19M 480M 185M 2.41B 186M 182M 7.64B -322M -277M -262M -238M -445M -30.82B -450M -3.12B -1.2B -15.63B -1.21B -1.18B -49.65B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
10/09/26 US$134.68 -2.35% 1,866,957
09/09/26 US$137.92 -3.06% 2,058,782
08/09/26 US$142.28 -3.53% 2,232,006
04/09/26 US$147.48 -2.06% 1,058,435
03/09/26 US$150.58 +1.65% 1,157,659
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
134.68USD
Average target price
171.91USD
Spread / Average Target
+27.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!